Open an account

Transcode Therapeutics

RNAZ · NASDAQ

$1.68−$0.02 (−1.18%)TodayMarket closed ·
Prev close $1.70

About RNAZ

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2021-04-28. The company is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The firm is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Employees
7
Headquarters
Boston, Massachusetts
Listed
Apr 28, 2021
Sector
Health Care
Industry
Biotechnology
Website
transcodetherapeutics.com

RNAZ key statistics

Market cap
28.44M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
55.92K
Volume
20.23K
Open price
$1.71
High today
$1.75
Low today
$1.60
52 Week high
$15.33
52 Week low
$1.52

Transcode Therapeutics (RNAZ) at a glance

Transcode Therapeutics (RNAZ) last traded at $1.68, with a market cap of 28.44M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.60 and $1.75. The current price is 4.8% above the day's low and 4.0% below its high.

Volume so far is 20.23K shares, below the average of 55.92K shares a day.

Over the past year Transcode Therapeutics has ranged from $1.52 to $15.33, and now sits 1% of the way up that range.

Transcode Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY24 it reported -$150.64 per share against an estimate of -$91.68.

RNAZ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 32.4% on average.

  1. Q4 FY22: reported -$295,680.00 per share against an estimate of -$286,513.91
  2. Q2 FY23: reported -$121,598.40 per share against an estimate of -$127,800.29
  3. Q3 FY23: reported -$62,092.80 per share against an estimate of -$56,548.80
  4. Q4 FY23: reported -$21,104.16 per share against an estimate of -$10,178.78
  5. Q1 FY24: reported -$498.96 per share against an estimate of -$659.74
  6. Q2 FY24: reported -$665.28 per share against an estimate of -$546.64
  7. Q3 FY24: reported -$147.84 per share against an estimate of -$461.82
  8. Q4 FY24: reported -$150.64 per share against an estimate of -$91.68

RNAZ news

  • Press releasePRNewswire

    TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026

  • Press releaseBusiness Wire

    Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

  • Press releasePRNewswire

    TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up

  • Press releasePRNewswire

    TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology

  • Press releasePRNewswire

    TransCode Therapeutics Announces Leadership Transition

  • Press releasePRNewswire

    TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

Similar companies

Companies in the same industry as Transcode Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.